<DOC>
	<DOCNO>NCT00427765</DOCNO>
	<brief_summary>Primary Objectives : 1 . To determine efficacy administer multiple dos intravenous ( i.v . ) busulfan dose 130 mg/m2 , yield systemic plasma drug exposure represent daily area plasma concentration versus time curve ( AUC ) approximately 5,000 mMol-min 4 day , follow i.v . melphalan dose 70 mg/m2 2 day adult patient receive autologous allogeneic transplantation lymphoid malignancy myeloma . 2 . To describe plasma pharmacokinetic ( PK ) profile busulfan melphalan regimen . 3 . To determine disease-free overall survival patient receive preparative regimen . 4 . To determine treatment-related morbidity mortality combination drug .</brief_summary>
	<brief_title>Busulfan Plus Melphalan Conditioning Regimen Lymphoid Malignancies Multiple Myeloma</brief_title>
	<detailed_description>Busulfan melphalan traditional alkylating agent design interfere production cancer cell DNA ( deoxyribonucleic acid ) RNA ( ribonucleic acid ) level . Before start treatment study , call `` screening test '' . These test help doctor decide eligible take part study . You complete physical exam , include routine blood ( 2-3 teaspoon ) urine test . Patients chest x-ray , heart scan , lung function test , bone marrow biopsy . Women able child must negative blood pregnancy test . If find eligible take part study , able start receive chemotherapy treatment busulfan melphalan . Participants agree optional blood draw describe first receive therapeutic `` trial dose '' busulfan vein test blood level time . This therapeutic trial dose busulfan 25 % ( 1 fourth ) full therapeutic dose drug . This information use decide future high-dose busulfan treatment receive . If agree optional blood draw , receive fix amount high-dose busulfan start . On 1st day hospitalization , receive fluid vein central venous catheter . If choose optional busulfan dose pharmacokinetic-based busulfan dosing , receive optional busulfan dose 9 day stem cell infusion ( Day 1 ) , follow rest day Day 2 . If choose receive fix dose busulfan , busulfan injected central venous catheter 3 hour , day , next 4 day ( Days 3-6 , end 3 day stem cell infusion day ) . Patients receive pharmacokinetic-based dosing busulfan also continue receive busulfan Days 3-6 . This follow melphalan patient , give central venous catheter 30 minute , day , 2 day , day 8 9 . Your stem cell infusion day Day 10 treatment . Patients receive 5 6 antigen matched-related allogeneic stem cell transplant unrelated allogeneic stem cell transplant also receive antithymocyte globulin ( ATG ) , vein , Days 7-9 , one day stem cell infusion . This give decrease risk GVHD graft rejection mismatch transplant . On Day 10 , healthy blood stem cell bone marrow donor give central catheter . This transplant date . You also receive several medication help treatment work help prevent infection immune system weak . Tacrolimus methotrexate give decrease risk graft-versus-host-disease ( GVHD ) . GVHD occur donor 's immune cell fight patient 's body . The tacrolimus start day transplant continue six month . Tacrolimus give vein first mouth able eat . Methotrexate give vein Days 11 , 13 , 16 , possibly Day 21 , 11 day transplant . Please note treatment date list use help explain general treatment plan . By standard medical convention , day stem cell infusion always list day zero . Therefore , day list different treatment plan describe protocol abstract . Sulfamethoxazole ( Bactrim ) pentamidine give fight bacteria . Bactrim give mouth count good . Pentamidine give vein count low . Acyclovir give first vein Valtrex ( valacyclovir ) give pill decrease risk viral infection . Granulocyte colony-stimulating factor ( G-CSF ) give help new bone marrow grow . It give injection skin transplant . It continue white blood cell reach acceptable level . Overall , drug give long 6 month possibly longer . Other medication may necessary . If allergic drug , change make . You hospital 3-4 week . You checkups every day discharge hospital . You see outpatient clinic least 3 time week blood count improve . You see doctor least every week 100 day bone marrow transplant . You must stay Houston time . After 100 day , return clinic accord individual physician 's recommendation . Some patient may need receive spinal tap instillation chemotherapy several time year transplantation . This patient previous clinical history leukemic involvement brain high risk develop leukemia relapse brain . The spinal tap perform clinic . You give local anesthetic low back site , small needle inserted space 2 spinal bone , small amount fluid bathe brain ( cerebrospinal fluid ) remove test , small amount chemotherapy give . Bone marrow sample take 1 month 3 month transplant . You also lung function test 3 month transplant . This investigational study . The FDA approve drug use study use stem cell transplantation . Up 168 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients lymphoid malignancy , include Hodgkin 's nonHodgkin 's lymphoma ( primary refractory recurrent ) , multiple myeloma ( beyond first complete remission unresponsive therapy . Complete remission multiple myeloma define absence detectable paraprotein serum and/or urine immunoelectrophoresis immunofixation , &lt; 5 % plasma cell bone marrow ) , qualify treatment protocols high priority . Age 18 65 year age . Adequate renal function define estimate serum creatinine clearance &gt; 50 ml/min serum creatinine &lt; 1.8 mg/dL . Adequate hepatic function , define serum glutamic pyruvic transaminase ( SGPT ) &lt; 3 * upper limit normal ; serum bilirubin alkaline phosphatase &lt; 2 * upper limit normal , consider clinically significant . Adequate pulmonary function Forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) , Capacity Lung Carbon Monoxide ( DLCO ) &gt; 50 % . Exceptions may allow patient pulmonary involvement discuss principal investigator ( PI ) . Adequate cardiac function leave ventricular ejection fraction &gt; /= 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . Zubrod performance score &lt; 2 . Patients receive allogeneic transplant must HLA match , one A , B , DR mismatch related donor . Unrelated donor must match A , B , DR ( define A , B serologic match DRB1 molecular match ) . Donor must willing donate peripheral blood bone marrow progenitor cell . Patient donor willing participate study provide write consent . Female patient must pregnant negative pregnancy . Patients unresolved grade &gt; /= 3 nonhematologic toxicity previous therapy . Patients grade 2 toxicity eligible discretion PI . Patients active Central Nervous System ( CNS ) disease . Evidence acute chronic active hepatitis cirrhosis . If positive hepatitis serology , discus Study Chairman consider liver biopsy . Uncontrolled infection , include Human immunodeficiency virus ( HIV ) Human Tlymphotropic virus Type I ( HTLV1 ) infection . Patients previous autologous allogeneic stem cell transplant past year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Autologous bone marrow</keyword>
	<keyword>BMT</keyword>
	<keyword>Peripheral blood stem cell transplant</keyword>
	<keyword>PBSCT</keyword>
</DOC>